SCHEMBL24656777

SCHEMBL24656777

Cn1cc(C(C)(C)C)c2cnccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.45
GSK3B P49841 2/20 0.45
NFATC1 O95644 1/20 0.45
HASPIN Q8TF76 1/20 0.41
S1PR1 P21453 4/20 0.37
S1PR3 Q99500 4/20 0.37
MAOA P21397 5/20 0.37
MAOB P27338 5/20 0.37
ACHE P22303 1/20 0.37
PDPK1 O15530 1/20 0.35
TGFBR1 P36897 1/20 0.35
IKBKE Q14164 1/20 0.35
TBK1 Q9UHD2 1/20 0.35
CYP2D6 P10635 1/20 0.35
SCN9A Q15858 1/20 0.34
HTR6 P50406 1/20 0.33
HTR1D P28221 1/20 0.33
ELANE P08246 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24654868 0.87 DYRK1A (0.56) DYRK1AGSK3BNFATC1HASPINS1PR1
SCHEMBL13041963 0.81 HTR6 (0.48) DYRK1AGSK3BNFATC1HASPINMAOA
SCHEMBL19869619 0.80 BRD4 (0.44) DYRK1AGSK3BNFATC1TGFBR1CYP2D6
SCHEMBL19869985 0.80 BRD4 (0.46) DYRK1AGSK3BNFATC1TGFBR1CYP2D6
SCHEMBL22482127 0.76 HASPIN (0.61) DYRK1AGSK3BNFATC1HASPINS1PR1
SCHEMBL21893483 0.76 DYRK1A (0.46) DYRK1AGSK3BNFATC1HASPINMAOA
SCHEMBL20674195 0.76 DYRK1A (0.46) DYRK1AGSK3BNFATC1HASPINS1PR1
SCHEMBL8738068 0.75 GPR84 (0.52)
SCHEMBL24654861 0.73 DYRK1A (0.44) DYRK1AGSK3BNFATC1HASPINMAOA
SCHEMBL10313372 0.72 MAOA (0.32) DYRK1AGSK3BNFATC1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP DYRK1A 2576/4885GSK3B 948/4885NFATC1 4595/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP DYRK1A 2576/4885GSK3B 948/4885NFATC1 4595/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP DYRK1A 2576/4885GSK3B 948/4885NFATC1 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.